Wedbush Lifts Earnings Estimates for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Wedbush boosted their FY2027 EPS estimates for shares of Neurocrine Biosciences in a note issued to investors on Monday, December 23rd. Wedbush analyst L. Chico now forecasts that the company will post earnings of $14.46 per share for the year, up from their previous estimate of $13.11. Wedbush currently has a “Outperform” rating and a $148.00 price target on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.94 per share. Wedbush also issued estimates for Neurocrine Biosciences’ FY2028 earnings at $17.74 EPS.

Several other research firms have also issued reports on NBIX. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Royal Bank of Canada lowered their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. HC Wainwright reiterated a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $166.29.

Neurocrine Biosciences Stock Up 1.8 %

Shares of Neurocrine Biosciences stock opened at $139.03 on Wednesday. Neurocrine Biosciences has a twelve month low of $110.95 and a twelve month high of $157.98. The stock has a market cap of $14.08 billion, a price-to-earnings ratio of 37.27 and a beta of 0.34. The company’s fifty day moving average is $125.15 and its 200 day moving average is $130.65.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. This trade represents a 30.32 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC bought a new stake in Neurocrine Biosciences in the 2nd quarter worth about $28,000. Innealta Capital LLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at approximately $30,000. Blue Trust Inc. increased its stake in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares in the last quarter. Plato Investment Management Ltd increased its stake in Neurocrine Biosciences by 44.1% in the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after buying an additional 130 shares in the last quarter. Finally, Truvestments Capital LLC bought a new stake in Neurocrine Biosciences during the 3rd quarter valued at approximately $63,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.